Cargando…
The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden
SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158378/ https://www.ncbi.nlm.nih.gov/pubmed/34070092 http://dx.doi.org/10.3390/cancers13102456 |
_version_ | 1783699874681716736 |
---|---|
author | Eriksson, Hanna Utjés, Deborah Olofsson Bagge, Roger Gillgren, Peter Isaksson, Karolin Lapins, Jan Schultz, Inkeri Leonardsson Lyth, Johan Andersson, Therese M.-L. |
author_facet | Eriksson, Hanna Utjés, Deborah Olofsson Bagge, Roger Gillgren, Peter Isaksson, Karolin Lapins, Jan Schultz, Inkeri Leonardsson Lyth, Johan Andersson, Therese M.-L. |
author_sort | Eriksson, Hanna |
collection | PubMed |
description | SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Proportions cured by surgery are low for sub-groups of stage II–III cutaneous melanoma showing that cure analyses can serve as a complement to established survival analyses. ABSTRACT: Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II–III cutaneous melanoma (CM) patients. Methods: 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Results: Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77–0.83) stage IIA; 0.62 (95% CI 0.59–0.66) stage IIB; 0.42 (95% CI 0.37–0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68–0.84) stage IIIA; 0.52 (95% CI 0.45–0.59) stage IIIB; 0.35 (95% CI 0.30–0.39) for stage IIIC–D). Conclusions: The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II–III CM, specifically within stages IIB–C CM. |
format | Online Article Text |
id | pubmed-8158378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81583782021-05-28 The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden Eriksson, Hanna Utjés, Deborah Olofsson Bagge, Roger Gillgren, Peter Isaksson, Karolin Lapins, Jan Schultz, Inkeri Leonardsson Lyth, Johan Andersson, Therese M.-L. Cancers (Basel) Article SIMPLE SUMMARY: Patients diagnosed with stage II–III cutaneous melanoma (CM) are at high risk of recurrences, but the CM-specific survival ranges from approximately 40–70%. Here, the cure proportions and survival among uncured stage II–III CM patients were estimated. The 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Proportions cured by surgery are low for sub-groups of stage II–III cutaneous melanoma showing that cure analyses can serve as a complement to established survival analyses. ABSTRACT: Background: Cure proportion represents the proportion of patients who experience the same mortality rate as the general population and can be estimated together with the survival of the proportion experiencing excess mortality (the uncured). The aim was to estimate the cure proportions and survival among uncured stage II–III cutaneous melanoma (CM) patients. Methods: 1- and 5-year relative survival ratios, cure proportions and the median survival times of uncured stage II–III CM patients in Sweden (n = 6466) were calculated based on data from the nationwide population-based Swedish Melanoma Register 2005–2013 with a follow-up through 2018. Results: Stages IIB and IIC showed significant differences in standardized cure proportions vs. stage IIA CM (0.80 (95% CI 0.77–0.83) stage IIA; 0.62 (95% CI 0.59–0.66) stage IIB; 0.42 (95% CI 0.37–0.46) for stage IIC). Significant differences in standardized cure proportions were found for stages IIIB and IIIC-D CM vs. stage IIIA (0.76 (95% CI 0.68–0.84) stage IIIA; 0.52 (95% CI 0.45–0.59) stage IIIB; 0.35 (95% CI 0.30–0.39) for stage IIIC–D). Conclusions: The results are emphasizing the poor prognosis with low proportions cured by surgery only for sub-groups of stage II–III CM, specifically within stages IIB–C CM. MDPI 2021-05-18 /pmc/articles/PMC8158378/ /pubmed/34070092 http://dx.doi.org/10.3390/cancers13102456 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eriksson, Hanna Utjés, Deborah Olofsson Bagge, Roger Gillgren, Peter Isaksson, Karolin Lapins, Jan Schultz, Inkeri Leonardsson Lyth, Johan Andersson, Therese M.-L. The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title | The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title_full | The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title_fullStr | The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title_full_unstemmed | The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title_short | The Proportion Cured of Patients with Resected Stage II–III Cutaneous Melanoma in Sweden |
title_sort | proportion cured of patients with resected stage ii–iii cutaneous melanoma in sweden |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158378/ https://www.ncbi.nlm.nih.gov/pubmed/34070092 http://dx.doi.org/10.3390/cancers13102456 |
work_keys_str_mv | AT erikssonhanna theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT utjesdeborah theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT olofssonbaggeroger theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT gillgrenpeter theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT isakssonkarolin theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT lapinsjan theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT schultzinkerileonardsson theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT lythjohan theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT anderssonthereseml theproportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT erikssonhanna proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT utjesdeborah proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT olofssonbaggeroger proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT gillgrenpeter proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT isakssonkarolin proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT lapinsjan proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT schultzinkerileonardsson proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT lythjohan proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden AT anderssonthereseml proportioncuredofpatientswithresectedstageiiiiicutaneousmelanomainsweden |